Attached files
file | filename |
---|---|
8-K - FORM 8-K - Bausch Health Companies Inc. | a59043e8vk.htm |
EX-10.1 - EX-10.1 - Bausch Health Companies Inc. | a59043exv10w1.htm |
Exhibit 99.1
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Laurie W. Little
949-461-6002
laurie.little@valeant.com
VALEANT PHARMACEUTICALS EXTENDS CONTRACT WITH J. MICHAEL
PEARSON AS CEO AND APPOINTS HIM AS CHAIRMAN OF THE BOARD
PEARSON AS CEO AND APPOINTS HIM AS CHAIRMAN OF THE BOARD
Mississauga, Ontario, March 22, 2011 Valeant Pharmaceuticals International, Inc. (NYSE:
VRX) (TSX: VRX) today announced the appointment of J. Michael Pearson, currently Valeants Chief
Executive Officer (CEO), as Chairman of the Board of Directors, replacing Robert A. Ingram, who
remains on the Valeant Board as an independent Board Director and Lead Director. Mr. Pearson will
continue in his role as CEO and has agreed to extend his contract through to February 2017.
I am honored that the Board has shown its confidence in me with this appointment and that by
extending my contract, allows me the privilege of leading this organization for the next six
years, stated J. Michael Pearson, chairman and chief executive officer. I continue to believe in
Valeants long-term potential and I look forward to working with our team to execute on our
strategy to become a leading specialty pharmaceutical company.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty
pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical
products primarily in the areas of neurology, dermatology and branded generics. More information
about Valeant can be found at www.valeant.com.